155 related articles for article (PubMed ID: 16378658)
1. Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion.
Tibaldi C; Bernardini I; Chella A; Russo F; Toma G; Tempestini F; Malventi M; Vasile E; Ambrosino N; Falcone A
Lung Cancer; 2006 Feb; 51(2):217-23. PubMed ID: 16378658
[TBL] [Abstract][Full Text] [Related]
2. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
3. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
Gridelli C; De Maio E; Barbera S; Sannicolo M; Piazza E; Piantedosi F; Brancaccio L; Morabito A; Maione P; Renda F; Signoriello G; Perrone F;
Lung Cancer; 2008 Jul; 61(1):67-72. PubMed ID: 18683299
[TBL] [Abstract][Full Text] [Related]
4. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
[TBL] [Abstract][Full Text] [Related]
8. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
9. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
10. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Xiong JP; Feng M; Qiu F; Xu J; Tao QS; Zhang L; Xiang XJ; Zhong LX; Yu F; Ma XT; Gong WY
Lung Cancer; 2008 May; 60(2):208-14. PubMed ID: 18023915
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
[TBL] [Abstract][Full Text] [Related]
16. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
[TBL] [Abstract][Full Text] [Related]
17. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
[TBL] [Abstract][Full Text] [Related]
19. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
